News

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...
The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...
Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.
Moderna expects many new products to launch in just a few years, so it's possible that in 10 years, Moderna could have about 10 products on the market.
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
The decision to cancel the Moderna contracts, undoubtedly driven by anti-vaccine crusader and HHS Secretary Robert F. Kennedy, Jr., puts the entire nation at risk, as does this administration’s ...
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.